Multiple Sclerosis vs Motor Neurone Disease — Clinical Trial Comparison
Multiple Sclerosis
Autoimmune demyelination of the central nervous system
VS
Motor Neurone Disease
Progressive degeneration of motor neurons (ALS)
Multiple sclerosis and motor neurone disease (MND/ALS) are both progressive neurological conditions, but they differ fundamentally in their mechanisms, disease trajectories, and treatment approaches. MS has a rapidly expanding range of disease-modifying therapies, while MND treatment options remain limited — making clinical trials especially important for MND patients.
Key Differences at a Glance
| Feature | Multiple Sclerosis | Motor Neurone Disease |
|---|---|---|
| Primary symptoms | Vision problems, fatigue, weakness, numbness, coordination issues | Progressive muscle weakness, wasting, cramps, speech/swallowing difficulty |
| Common subtypes | RRMS, SPMS, PPMS, CIS, radiologically isolated | Sporadic ALS, familial ALS, SOD1-mutant, C9orf72-positive, bulbar onset, limb onset |
| Severity scoring | EDSS, MSFC, relapse rate, MRI lesion count | ALSFRS-R, FVC (lung function), MRC strength grading |
| Disease trajectory | Relapsing-remitting in 85%; can progress to secondary progressive | Relentlessly progressive from diagnosis; median survival 2–5 years |
| NICE first-line | DMTs (interferon, glatiramer, dimethyl fumarate, teriflunomide) | Riluzole (modest survival benefit), edaravone (limited use) |
| Prevalence in UK | ~130,000 (1 in 500) | ~5,000 at any time (1 in 14,000) |
Clinical Trial Availability
| Trial Aspect | Multiple Sclerosis | Motor Neurone Disease |
|---|---|---|
| UK trials actively recruiting | 40–70 studies | 20–35 studies |
| Most common trial phase | Phase 2–3 | Phase 1–2 |
| Top interventions tested | Novel DMTs, B-cell depleters, stem cells, neurorehab, digital monitoring | Gene therapy, antisense oligonucleotides, neuroprotectives, stem cells, Riluzole combinations |
| Gene therapy trials | Limited (mostly stem cell) | Major focus (SOD1, C9orf72 targets) |
| Stem cell trials | HSCT for aggressive RRMS | Mesenchymal stem cells for neuroprotection |
| Digital/remote trials | Wearable monitoring, digital endpoints, tele-rehab | Remote outcome measures, digital speech analysis |
Exciting Emerging Treatments
Multiple Sclerosis Trials
- B-cell depleting therapies — next-generation anti-CD20 agents
- Bruton tyrosine kinase (BTK) inhibitors — oral agents targeting CNS inflammation
- Remyelination therapies — promoting repair of damaged myelin
- HSCT — autologous stem cell transplant for aggressive RRMS
- Neurorehabilitation tech — VR-based, robot-assisted rehab
- Gut microbiome interventions — targeting the MS-microbiome axis
Motor Neurone Disease Trials
- Antisense oligonucleotides — targeting SOD1 and C9orf72 mutations
- CRISPR/gene editing — potential one-time curative approach
- Tofersen — SOD1-targeted gene therapy (approved in US, trials expanding)
- Combination neuroprotective approaches — multi-target drug cocktails
- Stem cell therapy — mesenchymal and neural stem cell approaches
- Anti-sense and RNA therapies — precision targeting of genetic forms
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Multiple Sclerosis Trial Criteria
- Definite MS diagnosis (McDonald criteria) with objective evidence
- RRMS trials: documented relapses within past 12 months
- EDSS score range specified (e.g. 0–5.5 for relapsing trials)
- Prior DMT washout period required (varies by medication, 2–12 weeks)
- MRI activity required for most trials (gadolinium-enhancing lesions or new T2 lesions)
Motor Neurone Disease Trial Criteria
- Definite or probable ALS/MND diagnosis (El Escorial or Gold Coast criteria)
- ALSFRS-R score typically ≥ 24–30 (early to moderate disease)
- FVC typically ≥ 50–60% predicted (sufficient respiratory function)
- Disease duration usually ≤ 24 months from symptom onset
- Genetic subgroup trials require confirmed SOD1, C9orf72, or other specific mutation
Frequently Asked Questions
Can I join a clinical trial if I have both Multiple Sclerosis and Motor Neurone Disease?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Multiple Sclerosis typically has more actively recruiting trials in the UK. However, Motor Neurone Disease trials are often more novel in approach, particularly in emerging areas like gene therapy and precision medicine.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.